PHASE-XS: Creating New Pathways for Biologics through Advanced Market Solutions

The advent of biologics and biosimilars has revolutionized the pharmaceutical industry, by providing new therapeutic opportunities for various diseases. Advanced biotechnology products have aided in the management of variety of cancers and aided in the treatment of chronic illnesses such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and multiple sclerosis.

Get in touch with us to know more about the amazing PHASE-XS: https://www.coherentmarketinsights.com/phase-xs/request-a-call-back
I promise you won’t be disappointed.

Enbrel, Remicade, and Humira are few biologics products approved by the FDA a decade ago, and are effectively used for treatment of various chronic diseases. Various biopharmaceutical companies are increasingly getting involved in innovating new drugs with drug-device combinations, biosimilars, biomarkers, orphan drugs, and other novel products. According to the Biopharmaceutical Pipeline report 2016, there were about 6,300 products in clinical development comprising over 9,500 projects, globally. Of the projects in clinical development, 822 were determined to be covered by an orphan drug designation awarded by the FDA.

Companies developing biologic products have to be aware of its competitors by having sufficient knowledge about the type of products that are in the pipeline. For such information, innovation leaders in this industry can take aid from Coherent Market Insights’ database, called PHASE-XS.

PHASE-XS, is a database for complete clinical and market related information of drugs in clinical trials phase 3 and 4. It provides you with insights related to the pipeline developments by competitive companies in the field of biopharmaceutical.

PHASE-XS helps you to stay updated with respect to the pipeline developments. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included in the PHASE-XS data base.

To know more about PHASE-XS and biosimilar opportunity in the market, you can click in the below link @ www.coherentmarketinsights.com/phase-xs/

Some of the specialized features PHASE-XS imbibes to help clients include:

 Identify target products for biosimilars through patent expiry of biologics
 Identify if there are any studies for the extension of indications of already approved products
 Identify the products with significant revenue opportunity
 Identify an ideal trail design with a competitive edge
 Identify strategic market access programs to launch new drugs

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.